Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2390-2394

  Sader, Helio S ^a,b   Rhomberg, Paul R ^a   Farrell, David J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CXA 101; CXA 201; IMIPENEM; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; BROTH DILUTION; CITROBACTER; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEUS; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA;

BACTEROIDES FRAGILIS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA;

EID: 79955536362     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01737-10     Document Type: Article

References (11)

1. Bulik, C. C., H. Christensen, and D. P. Nicolau. 2010. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559.
2. Castanheira, M., H. S. Sader, and R. N. Jones. 2010. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug Resist. 16:61-65.
3. Clinical and Laboratory Standards Institute. 2007. M11-A7. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard: seventh edition. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: eighth edition. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2011. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Ge, Y., M. J. Whitehouse, I. Friedland, and G. H. Talbot. 2010. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. 54:3427-3431.
7. Juan, C., L. Zamorano, J. L. Perez, Y. Ge, and A. Oliver. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 54:846-851.
8. Livermore, D. M., S. Mushtaq, and Y. Ge. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1972-1974.
9. Livermore, D. M., S. Mushtaq, Y. Ge, and M. Warner. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406.
10. Moya, B., et al. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217.
11. Takeda, S., Y. Ishii, K. Hatano, K. Tateda, and K. Yamaguchi. 2007. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:443-445.